Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions

Nature Reviews Cancer

Volumn 14, Issue 6, 2014, Pages 395-405

  Steenbergen, Renske D M ^a   Snijders, Peter J F ^a   Heideman, Daniëlle A M ^a   Meijer, Chris J L M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; MICRORNA; MOLECULAR MARKER; PROTEIN E6; PROTEIN E7; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER SCREENING; CHROMOSOME ABERRATION; DNA METHYLATION; EMERGENCY HEALTH SERVICE; EPIGENETICS; GENE MUTATION; HOST CELL; HUMAN; NONHUMAN; PRECANCER; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX EPITHELIUM; WART VIRUS;

CELL TRANSFORMATION, NEOPLASTIC; CERVICAL INTRAEPITHELIAL NEOPLASIA; EPIGENOMICS; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 84901434075     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3728     Document Type: Review

References (127)

1. Arbyn, M. et al. Worldwide burden of cervical cancer in 2008. Ann. Oncol. 22, 2675-2686 (2011).
2. Ferlay, J. et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127, 2893-2917 (2010).
3. Walboomers, J. M. et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189, 12-19 (1999).
4. Baseman, J. G. & Koutsky, L. A. The epidemiology of human papillomavirus infections. J. Clin. Virol. 32 (Suppl. 1), S16-S24 (2005).
5. IARC. A review of human carcinogens-PartB: biological agents. 100B, (2011).
6. Snijders, P. J., Steenbergen, R. D., Heideman, D. A. & Meijer, C. J. HPV-mediated cervical carcinogenesis: concepts and clinical implications. J. Pathol. 208, 152-164 (2006).
7. McCredie, M. R. et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 9, 425-434 (2008).
8. Vink, M. A. et al. Clinical progression of high-grade cervical intraepithelial neoplasia: estimating the time to preclinical cervical cancer from doubly censored national registry data. Am. J. Epidemiol. 178, 1161-1169 (2013).
9. Peto, J., Gilham, C., Fletcher, O. & Matthews, F. E. The cervical cancer epidemic that screening has prevented in the UK. Lancet 364, 249-256 (2004).
10. Doorbar, J. Molecular biology of human papillomavirus infection and cervical cancer. Clin. Sci. 110, 525-541 (2006).
11. Stoler, M. H. et al. Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. Hum. Pathol. 23, 117-128 (1992).
12. Crum, C. P., Nagai, N., Levine, R. U. & Silverstein, S. In situ hybridization analysis of HPV 16 DNA sequences in early cervical neoplasia. Am. J. Pathol. 123, 174-182 (1986).
13. Chow, L. T., Broker,T. R., & Steinberg, B. M. The natural history of human papillomavirus infections of the mucosal epithelia. APMIS 118, 422-449 (2010).
14. Stern, P. L. et al. Therapy of human papillomavirus-related disease. Vaccine 30 (Suppl. 5), F71-F82 (2012).
15. zur Hausen, H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J. Natl Cancer Inst. 92, 690-698 (2000).
16. Schwarz, E. et al. Structure and transcription of human papillomavirus sequences in cervical-carcinoma cells. Nature 314, 111-114 (1985).
17. Duensing, S. & Munger, K. The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability. Cancer Res. 62, 7075-7082 (2002).
18. Bhattacharjee, B. & Sengupta, S. CpG methylation of HPV 16 LCR at E2 binding site proximal to P97 is associated with cervical cancer in presence of intact E2. Virology 354, 280-285 (2006).
19. Herfs, M. et al. A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. Proc. Natl Acad. Sci. USA 109, 10516-10521 (2012).
20. Mcnairn, A. J. & Guasch, G. Epithelial transition zones: merging microenvironments, niches, and cellular transformation. Eur. J. Dermatol. 21 (Suppl. 2), 21-28 (2011).
21. Herfs, M. et al. Cervical squamocolumnar junction-specific markers define distinct, clinically relevant subsets of low-grade squamous intraepithelial lesions. Am. J. Surg. Pathol. 37, 1311-1318 (2013).
22. de Martel, C. et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 13, 607-615 (2012).
23. Korzeniewski, N., Spardy, N., Duensing, A. & Duensing, S. Genomic instability and cancer: lessons learned from human papillomaviruses. Cancer Lett. 305, 113-122 (2011).
24. Moody, C. A. & Laimins, L. A. Human papillomavirus oncoproteins: pathways to transformation. Nature Rev. Cancer 10, 550-560 (2010).
25. Klingelhutz, A. J. & Roman, A. Cellular transformation by human papillomaviruses: lessons learned by comparing high-and low-risk viruses. Virology 424, 77-98 (2012).
26. McLaughlin-Drubin, M. E. & Munger, K. Biochemical and functional interactions of human papillomavirus proteins with polycomb group proteins. Viruses. 5, 1231-1249 (2013).
27. Au Yeung, C. L. et al. HPV-16 E6 upregulation of DNMT1 through repression of tumor suppressor p53. Oncol. Rep. 24, 1599-1604 (2010).
28. Burgers, W. A. et al. Viral oncoproteins target the DNA methyltransferases. Oncogene 26, 1650-1655 (2007).
29. Wilting, S. M. et al. Increased gene copy numbers at chromosome 20q are frequent in both squamous cell carcinomas and adenocarcinomas of the cervix. J. Pathol. 209, 220-230 (2006).
30. Sawada, M. et al. Increased expression of DNA methyltransferase 1 (DNMT1) protein in uterine cervix squamous cell carcinoma and its precursor lesion. Cancer Lett. 251, 211-219 (2007).
31. Leonard, S. M. et al. Oncogenic human papillomavirus imposes an instructive pattern of DNA methylation changes which parallel the natural history of cervical HPV infection in young women. Carcinogenesis 33, 1286-1293 (2012).
32. Hyland, P. L. et al. Evidence for alteration of EZH2, BMI1, and KDM6A and epigenetic reprogramming in human papillomavirus type 16 E6/E7-expressing keratinocytes. J. Virol. 85, 10999-11006 (2011).
33. Laughlin-Drubin, M. E., Crum, C. P. & Munger, K. Human papillomavirus E7 oncoprotein induces KDM6A and KDM6B histone demethylase expression and causes epigenetic reprogramming. Proc. Natl Acad. Sci. USA 108, 2130-2135 (2011).
34. Wentzensen, N. & von Knebel, D. M. Biomarkers in cervical cancer screening. Dis. Markers 23, 315-330 (2007).
35. Martinez, I. et al. Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells. Oncogene 27, 2575-2582 (2008).
36. Wang, X. et al. Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6. RNA 15, 637-647 (2009).
37. Au Yeung, C. L., Tsang, T. Y., Yau, P. L. & Kwok, T. T. Human papillomavirus type 16 E6 induces cervical cancer cell migration through the p53/microRNA-23b/urokinase-type plasminogen activator pathway. Oncogene 30, 2401-2410 (2011).
38. Melar-New, M. & Laimins, L. A. Human papillomaviruses modulate expression of microRNA 203 upon epithelial differentiation to control levels of p63 proteins. J. Virol. 84, 5212-5221 (2010).
39. Zheng, Z. M. & Wang, X. Regulation of cellular miRNA expression by human papillomaviruses. Biochim. Biophys. Acta 1809, 668-677 (2011).
40. Qian, K. et al. Identification and validation of human papillomavirus encoded microRNAs. PLoS ONE. 8, e70202 (2013).
41. Agarwal, S. M., Raghav, D., Singh, H. & Raghava, G. P. CCDB: a curated database of genes involved in cervix cancer. Nucleic Acids Res. 39, D975-D979 (2011).
42. Thomas, L. K. et al. Chromosomal gains and losses in human papillomavirus-associated neoplasia of the lower genital tract-A systematic review and meta-analysis. Eur. J. Cancer 50, 85-98 (2014).
43. Bierkens, M. et al. Focal aberrations indicate EYA2 and hsa-miR-375 as oncogene and tumor suppressor in cervical carcinogenesis. Genes Chromosomes. Cancer 52, 56-68 (2013).
44. Wang, F. et al. miR-375 is down-regulated in squamous cervical cancer and inhibits cell migration and invasion via targeting transcription factor SP1. Am. J. Pathol. 179, 2580-2588 (2011).
45. Akagi, K. et al. Genome-wide analysis of HPV integration in human cancers reveals recurrent, focal genomic instability. Genome Res. 24, 185-199 (2014).
46. Forbes, S. A. et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 39, D945-D950 (2011).
47. Wright, A. A. et al. Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer 119, 3776-3783 (2013).
48. Ojesina, A. I. et al. Landscape of genomic alterations in cervical carcinomas. Nature 506, 371-375 (2013).
49. Shen, H. & Laird, P. W. Interplay between the cancer genome and epigenome. Cell 153, 38-55 (2013).
50. Clarke, M. A. et al. Human papillomavirus DNA methylation as a potential biomarker for cervical cancer. Cancer Epidemiol. Biomarkers Prev. 21, 2125-2137 (2012).
51. Johannsen, E. & Lambert, P. F. Epigenetics of human papillomaviruses. Virology 445, 205-212 (2013).
52. Doerfler, W. et al. The fate of foreign DNA in mammalian cells and organisms. Dev. Biol. 106, 89-97 (2001).
53. Fernandez, A. F. et al. The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. Genome Res. 19, 438-451 (2009).
54. Vinokurova, S. & von Knebel, D. M. Differential methylation of the HPV 16 upstream regulatory region during epithelial differentiation and neoplastic transformation. PLoS ONE. 6, e24451 (2011).
55. Thain, A., Jenkins, O., Clarke, A. R. & Gaston, K. CpG methylation directly inhibits binding of the human papillomavirus type 16 E2 protein to specific DNA sequences. J. Virol. 70, 7233-7235 (1996).
56. Wentzensen, N., Sherman, M. E., Schiffman, M. & Wang, S. S. Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. Gynecol. Oncol. 112, 293-299 (2009).
57. Szalmas, A. & Konya, J. Epigenetic alterations in cervical carcinogenesis. Semin. Cancer Biol. 19, 144-152 (2009).
58. Chen, Y. C. et al. Methylomics analysis identifies epigenetically silenced genes and implies an activation of β-catenin signaling in cervical cancer. Int. J. Cancer 135, 117-127 (2013).
59. Lendvai, A. et al. Genome-wide methylation profiling identifies hypermethylated biomarkers in high-grade cervical intraepithelial neoplasia. Epigenetics 7, 1268-1278 (2012).
60. Farkas, S. A., Milutin-Gasperov, N., Grce, M. & Nilsson, T. K. Genome-wide DNA methylation assay reveals novel candidate biomarker genes in cervical cancer. Epigenetics. 8, 1213-1225 (2013).
61. Brebi, P. et al. Genome-wide methylation profiling reveals Zinc finger protein 516 and FK-506-binding protein 6 promoters frequently methylated in cervical neoplasia, associated with HPV status and ethnicity in a Chilean population. Epigenetics. 9, 308-317 (2013).
62. Steenbergen, R. D. et al. Methylation-specific digital karyotyping of HPV16E6E7-expressing human keratinocytes identifies novel methylation events in cervical carcinogenesis. J. Pathol. 231, 53-62 (2013).
63. Huang, R. L. et al. Methylomic analysis identifies frequent DNA methylation of zinc finger protein 582 (ZNF582) in cervical neoplasms. PLoS ONE 7, e41060 (2012).
64. Chung, M. T. et al. SFRP1 and SFRP2 suppress the transformation and invasion abilities of cervical cancer cells through Wnt signal pathway. Gynecol. Oncol. 112, 646-653 (2009).
65. Steenbergen, R. D. et al. TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia. J. Natl Cancer Inst. 96, 294-305 (2004).
66. Overmeer, R. M. et al. Association between dense CADM1 promoter methylation and reduced protein expression in high-grade CIN and cervical SCC. J. Pathol. 215, 388-397 (2008).
67. Overmeer, R. M. et al. Repression of MAL tumour suppressor activity by promoter methylation during cervical carcinogenesis. J. Pathol. 219, 327-336 (2009).
68. Huisman, C. et al. Functional validation of putative tumor suppressor gene C13ORF18 in cervical cancer by artificial transcription factors. Mol. Oncol. 7, 669-679 (2013).
69. Lee, E. J. et al. Dkk3, downregulated in cervical cancer, functions as a negative regulator of β-catenin. Int. J. Cancer 124, 287-297 (2009).
70. Kaczkowski, B., Morevati, M., Rossing, M., Cilius, F. & Norrild, B. A decade of global mRNA and miRNA profiling of HPV-positive cell lines and clinical specimens. Open. Virol. J. 6, 216-231 (2012).
71. Saavedra, K. P., Brebi, P. M. & Roa, J. C. Epigenetic alterations in preneoplastic and neoplastic lesions of the cervix. Clin. Epigenet. 4, 13 (2012).
72. Lee, J. W. et al. Altered MicroRNA expression in cervical carcinomas. Clin. Cancer Res. 14, 2535-2542 (2008).
73. Wilting, S. M. et al. Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. Mol. Cancer 9, 167 (2010).
74. Wilting, S. M. et al. Methylation-mediated transcriptional repression of microRNAs during cervical carcinogenesis. Epigenetics. 8, 220-228 (2013).
75. Wang, X. et al. Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS ONE. 3, e2557 (2008).
76. Wilting, S. M. et al. Altered microRNA expression associated with chromosomal changes contributes to cervical carcinogenesis. Oncogene 32, 106-116 (2013).
77. Li, Y. et al. Progressive miRNA expression profiles in cervical carcinogenesis and identification of HPV-related target genes for miR-29. J. Pathol. 224, 484-495 (2011).
78. Cheung, T. H. et al. Dysregulated microRNAs in the pathogenesis and progression of cervical neoplasm. Cell Cycle 11, 2876-2884 (2012).
79. Pereira, P. M., Marques, J. P., Soares, A. R., Carreto, L. & Santos, M. A. MicroRNA expression variability in human cervical tissues. PLoS ONE 5, e11780 (2010).
80. Scotto, L. et al. Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: potential role in progression. Genes Chromosomes Cancer 47, 755-765 (2008).
81. Muralidhar, B. et al. Functional evidence that Drosha overexpression in cervical squamous cell carcinoma affects cell phenotype and microRNA profiles. J. Pathol. 224, 496-507 (2011).
82. Yao, T. et al. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in cervical cancer. Virol. J. 10, 175 (2013).
83. Botezatu, A. et al. Quantitative analysis of the relationship between microRNA124a,-34b and-203 gene methylation and cervical oncogenesis. Mol. Med. Rep. 4, 121-128 (2011).
84. Yang, H. P. et al. Clinical and pathological heterogeneity of cervical intraepithelial neoplasia grade 3. PLoS ONE 7, e29051 (2012).
85. Wentzensen, N. et al. Heterogeneity of high-grade cervical intraepithelial neoplasia related to HPV16: implications for natural history and management. Int. J. Cancer 132, 148-154 (2013).
86. Castle, P. E., Gravitt, P. E., Wentzensen, N. & Schiffman, M. A descriptive analysis of prevalent versus incident cervical intraepithelial neoplasia grade 3 following minor cytologic abnormalities. Am. J. Clin. Pathol. 138, 241-246 (2012).
87. Ostor, A. G. Natural history of cervical intraepithelial neoplasia: a critical review. Int. J. Gynecol. Pathol. 12, 186-192 (1993).
88. Bierkens, M. et al. Chromosomal profiles of high-grade cervical intraepithelial neoplasia relate to duration of preceding high-risk human papillomavirus infection. Int. J. Cancer 131, E579-E585 (2011).
89. Bierkens, M. et al. CADM1 and MAL promoter methylation levels in hrHPV-positive cervical scrapes increase proportional to degree and duration of underlying cervical disease. Int. J. Cancer 133, 1293-1299 (2013).
90. Arbyn, M. et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 30 (Suppl. 5), F88-F99 (2012).
91. Ronco, G. et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 383, 524-532 (2014).
92. Katki, H. A. et al. Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines. J. Low Genit. Tract. Dis. 17, S28-S35 (2013).
93. Dijkstra, M. G. et al. Primary hrHPV DNA testing in cervical cancer screening: how to manage screen-positive women? A POBASCAM trial substudy. Cancer Epidemiol. Biomarkers Prev. 23, 55-63 (2013).
94. Rijkaart, D. C. et al. HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications. Br. J. Cancer 106, 975-981 (2012).
95. Arbyn, M., Ronco, G., Cuzick, J., Wentzensen, N. & Castle, P. E. How to evaluate emerging technologies in cervical cancer screening? Int. J. Cancer 125, 2489-2496 (2009).
96. Pepe, M. S. et al. Phases of biomarker development for early detection of cancer. J. Natl Cancer Inst. 93, 1054-1061 (2001).
97. Pepe, M. S., Feng, Z., Janes, H., Bossuyt, P. M. & Potter, J. D. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J. Natl Cancer Inst. 100, 1432-1438 (2008).
98. Carozzi, F. et al. Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. Lancet Oncol. 14, 168-176 (2013).
99. Petry, K. U. et al. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology. Gynecol. Oncol. 121, 505-509 (2011).
100. Conesa-Zamora, P. Role of cell cycle biomarkers in human papillomavirus related uterine lesions. Curr. Pharm. Des. 19, 1412-1424 (2013).
101. Reuschenbach, M. & von Knebel, D. M. Diagnostic tests for the detection of human papillomavirus-associated cervical lesions. Curr. Pharm. Des. 19, 1358-1370 (2013).
102. Snijders, P. J. et al. High-risk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening. Int. J. Cancer 132, 2223-2236 (2013).
103. Arbyn, M. et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol. 15, 172-183 (2014).
104. Brink, A. A. et al. High concordance of results of testing for human papillomavirus in cervicovaginal samples collected by two methods, with comparison of a novel self-sampling device to a conventional endocervical brush. J. Clin. Microbiol. 44, 2518-2523 (2006).
105. Kalantari, M. et al. Methylation of human papillomavirus 16, 18, 31, and 45 L2 and L1 genes and the cellular DAPK gene: Considerations for use as biomarkers of the progression of cervical neoplasia. Virology 448, 314-321 (2014).
106. Lai, H. C. et al. Quantitative DNA methylation analysis detects cervical intraepithelial neoplasms type 3 and worse. Cancer 116, 4266-4274 (2010).
107. Eijsink, J. J. et al. Detection of cervical neoplasia by DNA methylation analysis in cervico-vaginal lavages, a feasibility study. Gynecol. Oncol. 120, 280-283 (2011).
108. Overmeer, R. M. et al. Combined CADM1 and MAL promoter methylation analysis to detect (pre-) malignant cervical lesions in high-risk HPV-positive women. Int. J. Cancer 129, 2218-2225 (2011).
109. Hesselink, A. T. et al. Combined promoter methylation analysis of CADM1 and MAL: An objective triage tool for high-risk human papillomavirus DNA-positive women. Clin. Cancer Res. 17, 2459-2465 (2011).
110. Hesselink, A. T. et al. Methylation marker analysis of self-sampled cervico-vaginal lavage specimens to triage high-risk HPV-positive women for colposcopy. Int. J. Cancer http://dx.doi.org/10.1002/ijc.28723 (2014).
111. Verhoef, V. M. et al. A randomised controlled trial on triage of HPV positive women on self-collected cervico-vaginal specimens: direct methylation marker testing versus indirect cytology. Lancet Oncol. 15, 315-322 (2014).
112. Widschwendter, A. et al. Analysis of aberrant DNA methylation and human papillomavirus DNA in cervicovaginal specimens to detect invasive cervical cancer and its precursors. Clin. Cancer Res. 10, 3396-3400 (2004).
113. Huang, T. H. et al. Quantitative analysis of methylation status of the PAX1 gene for detection of cervical cancer. Int. J. Gynecol. Cancer 20, 513-519 (2010).
114. Cuzick, J. et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int. J. Cancer 119, 1095-1101 (2006).
115. Kitchener, H. C., Castle, P. E. & Cox, J. T. Chapter 7: Achievements and limitations of cervical cytology screening. Vaccine 24 (Suppl. 3), 63-70 (2006).
116. Bruinsma, F. J. & Quinn, M. A. The risk of preterm birth following treatment for precancerous changes in the cervix: a systematic review and meta-analysis. BJOG. 118, 1031-1041 (2011).
117. Arbyn, M. et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ 337, a1284 (2008).
118. Kyrgiou, M. et al. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 367, 489-498 (2006).
119. Kocken, M. et al. Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. Lancet Oncol. 12, 441-450 (2011).
120. Kocken, M. et al. High-risk human papillomavirus testing versus cytology in predicting post-treatment disease in women treated for high-grade cervical disease: a systematic review and meta-analysis. Gynecol. Oncol. 125, 500-507 (2012).
121. Gnyszka, A., Jastrzebski, Z. & Flis, S. DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer. Anticancer Res. 33, 2989-2996 (2013).
122. Lopez-Serra, P. & Esteller, M. DNA methylation-associated silencing of tumor-suppressor microRNAs in cancer. Oncogene 31, 1609-1622 (2012).
123. Wojdacz, T. K. & Dobrovic, A. Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res. 35, e41 (2007).
124. Snellenberg, S. et al. Development of a multiplex methylation-specific PCR as candidate triage test for women with an HPV-positive cervical scrape. BMC. Cancer 12, 551 (2012).
125. Eads, C. A. et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res. 28, E32 (2000).
126. Mikeska, T., Felsberg, J., Hewitt, C. A. & Dobrovic, A. Analysing DNA methylation using bisulphite pyrosequencing. Methods Mol. Biol. 791, 33-53 (2011).
127. Taylor, K. H. et al. Ultradeep bisulfite sequencing analysis of DNA methylation patterns in multiple gene promoters by 454 sequencing. Cancer Res. 67, 8511-8518 (2007).